Dataset of endo- and xenobiotic inhibition of CYP2B6: Comparison to CYP3A4.
Adverse drug reactions
CYP2B6
CYP3A4
Enzyme inhibition
Lipids
Mixtures
Journal
Data in brief
ISSN: 2352-3409
Titre abrégé: Data Brief
Pays: Netherlands
ID NLM: 101654995
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
07
02
2022
revised:
21
02
2022
accepted:
28
02
2022
entrez:
14
3
2022
pubmed:
15
3
2022
medline:
15
3
2022
Statut:
epublish
Résumé
Cytochrome P450 2B6 (CYP2B6) is a human enzyme important in chemical detoxification, steroid and fatty acid metabolism that is primarily hepatic. Therefore, induction or inhibition of CYP2B6 may perturb endo- and xenobiotic metabolism and cause adverse reactions. Recent research indicates that mice lacking Cyp2b enzymes are obese with liver steatosis [1] (Heintz et al.,
Identifiants
pubmed: 35282180
doi: 10.1016/j.dib.2022.108013
pii: S2352-3409(22)00224-4
pmc: PMC8914530
doi:
Types de publication
Journal Article
Langues
eng
Pagination
108013Subventions
Organisme : NIEHS NIH HHS
ID : R15 ES017321
Pays : United States
Informations de copyright
© 2022 The Author(s). Published by Elsevier Inc.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships which have or could be perceived to have influenced the work reported in this article.
Références
J Nutr Biochem. 2019 Aug;70:125-137
pubmed: 31202118
Toxicol Sci. 2009 Jan;107(1):93-105
pubmed: 18832183
Pharmacol Ther. 2013 Apr;138(1):103-41
pubmed: 23333322
Toxicol Sci. 2005 Oct;87(2):520-8
pubmed: 16002478
Curr Drug Metab. 2008 Sep;9(7):598-610
pubmed: 18781911
Chemosphere. 2017 Dec;189:699-708
pubmed: 28968576
Mol Cell Biol. 2000 May;20(9):2951-8
pubmed: 10757780